Luciane Amado Leon

Luciane Amado Leon

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2006 in Memórias do Instituto Oswaldo Cruz
Verified
Journal Article
Open access
PDF file
LLLuciane Amado Leon
Luciane Amado Leon
LVLivia Melo Villar
Livia Melo Villar
VPVanessa de Paula
Vanessa de Paula
AAAdilson J de Almeida
Adilson J de Almeida
AGAna Maria C Gaspar
Ana Maria C Gaspar
In this report, we examine the adaptability of commercially available serological kits to detect antibodies markers for viral hepatitis in oral fluid samples. We also assessed the prevalence of hepatitis A, B, and C virus-specific antibodies, and related risk factors for these infectious diseases through sensitivity of the tests in saliva samples to evaluate if oralfluid can be an alternative tool to substitute serum in diagnosis of acute viral hepatitis and in epidemiological studies. One hundred and ten paired serum and saliva specimens from suspect patients of having acute hepatitis were collected to detect antibodies to hepatitis A (total and IgM), hepatitis B (anti-HBs, total anti-HBc and IgM anti-HBc), and hepatitis C (anti-HCV) using commercially available enzyme-linked immunossorbent assay (EIA). In relation to serum samples, oral fluid assay sensitivity and specificity were as follows: 87 and 100% for total anti-HAV, 79 and 100% for anti-HAVIgM, 6 and 95% for anti-HBs, 13 and 100%for total anti-HBc, 100 and 100% for anti-HBc IgM, and 75 and 100% for anti-HCV The consistency observed between antibodies tests in saliva and expected risk factors for hepatitis A and C suggests that the saliva method could replace serum in epidemiological studies for hepatitis A and C.

1 March 2008 in Journal of Virological Methods
Verified
Journal Article
Closed access
LLLuciane Amado Leon
Luciane Amado Leon
LVLivia Melo Villar
Livia Melo Villar
VPVanessa de Paula
Vanessa de Paula
AGAna Maria C. Gaspar
Ana Maria C. Gaspar

22 December 2009 in International Journal of Experimental Pathology
Verified
Journal Article
Closed access
PDF file
LLLuciane Amado Leon
Luciane Amado Leon
RMRenato Sergio Marchevsky
Renato Sergio Marchevsky
VPVanessa de Paula
Vanessa de Paula
CHCleber Hooper
Cleber Hooper
MFMarcos da S. Freire
Marcos da S. Freire
MPMarcelo A. Pinto
Marcelo A. Pinto

13 January 2021 in Future Microbiology
Verified
Journal Article
Closed access
RGRita de Cássia Nasser Cubel Garcia
Rita de Cássia Nasser Cubel Garcia
LLLuciane Amado Leon
Luciane Amado Leon
Since the first evidence of human parvovirus B19 (B19V) infection in late 80s, several studies have been conducted to clarify the spectrum of clinical diseases in Brazil. B19V infection is prevalen...

16 March 2011 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
LLLuciane Amado Leon
Luciane Amado Leon
LVLivia Melo Villar
Livia Melo Villar
VPVanessa de Paula
Vanessa de Paula
MPMarcelo Alves Pinto
Marcelo Alves Pinto
AGAna Maria Coimbra Gaspar
Ana Maria Coimbra Gaspar

8 May 2023 in Viruses
Verified
Journal Article
Open access
PDF file
DMDaniela Palheiro Mendes-de-Almeida
Daniela Palheiro Mendes-de-Almeida
JBJoanna Paes Barreto Bokel
Joanna Paes Barreto Bokel
AAArthur Daniel Rocha Alves
Arthur Daniel Rocha Alves
AVAlexandre Gomes Vizzoni
Alexandre Gomes Vizzoni
ITIsabel Cristina Ferreira Tavares
Isabel Cristina Ferreira Tavares
LLLuciane Amado Leon
Luciane Amado Leon
Parvovirus B19 (B19V) infection varies clinically depending on the host’s immune status. Due to red blood cell precursors tropism, B19V can cause chronic anemia and transient aplastic crisis in patients with immunosuppression or chronic hemolysis. We report three rare cases of Brazilian adults living with human immunodeficiency virus (HIV) with B19V infection. All cases presented severe anemia and required red blood cell transfusions. The first patient had low CD4+ counts and was treated with intravenous immunoglobulin (IVIG). As he remained poorly adherent to antiretroviral therapy (ART), B19V detection persisted. The second patient had sudden pancytopenia despite being on ART with an undetectable HIV viral load. He had historically low CD4+ counts, fully responded to IVIG, and had undiagnosed hereditary spherocytosis. The third individual was recently diagnosed with HIV and tuberculosis (TB). One month after ART initiation, he was hospitalized with anemia aggravation and cholestatic hepatitis. An analysis of his serum revealed B19V DNA and anti-B19V IgG, corroborating bone marrow findings and a persistent B19V infection. The symptoms resolved and B19V became undetectable. In all cases, real time PCR was essential for diagnosing B19V. Our findings showed that adherence to ART was crucial to B19V clearance in HIV-patients and highlighted the importance of the early recognition of B19V disease in unexplained cytopenias.